1. Which of the following enzymes in the B-cell receptor (BCR) pathway are targeted by agents that are currently FDA approved?

2. Which of the following have been proposed as potential BTK resistance mitigation strategies?

3. Lymphocytosis with BTK inhibitor initiation is:

4. ML is a newly-diagnosed CLL patient taking ibrutinib. When is it clinically appropriate to switch ML to acalabrutinib?

« Return to Activity